Samsung Bioepis acquires product approval of ‘Samfenet,’ Herceptin biosimilar

‘SB3(product name: Samfenet, generic name: trastuzumab),’ a Samsung Bioepis’ cancer therapy biosimilar, acquire product approval from the Ministry of Food and Drug Safety on the 8^th.

Samfenet is a biosimilar of ‘Herceptin(trastuzumab),’ a antibody for various cancers, such as metastatic breast cancer, early breast cancer and metastatic gastric cancer, sold by a Swiss pharmaceutical company Roc...